Abstract
Tumors are complex tissues composed of different cell types that interact with one another by building up complicated intra-and intercellular signal networks. In addition to the proliferating cancer cells, tumors also contain normal cells which are recruited and eroded by cancer cells to form tumor-supportive stroma and these natively normal stromal cells actively participate in the tumor development and progression by editing some of the behaviors of cancer cells and creating a tumor microenvironment to foster the rapid growth and proliferation of cancer cells. Therefore, the genetically mutated cancer cells are the cell of origin and driving forces for tumor development and progression. Selectively targeting cancer cells to induce tumor cell death and intercepting or normalizing the interaction signal network between the cancer and stromal cells are the bases for current cancer therapies. Identification of the mutated components in the intrinsic and extrinsic apoptotic pathways in cancer cells and designing small molecule mimetics or agonists to eradicate cancer cells by selectively targeting these mutations represent the attractive strategies for modern cancer therapy.
Keywords: Apoptosis, chemotherapy, TRAIL, p53, BAX, cancer drug targets, drug resistance.
Current Cancer Therapy Reviews
Title:Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Volume: 10 Issue: 1
Author(s): Shulin Wang
Affiliation:
Keywords: Apoptosis, chemotherapy, TRAIL, p53, BAX, cancer drug targets, drug resistance.
Abstract: Tumors are complex tissues composed of different cell types that interact with one another by building up complicated intra-and intercellular signal networks. In addition to the proliferating cancer cells, tumors also contain normal cells which are recruited and eroded by cancer cells to form tumor-supportive stroma and these natively normal stromal cells actively participate in the tumor development and progression by editing some of the behaviors of cancer cells and creating a tumor microenvironment to foster the rapid growth and proliferation of cancer cells. Therefore, the genetically mutated cancer cells are the cell of origin and driving forces for tumor development and progression. Selectively targeting cancer cells to induce tumor cell death and intercepting or normalizing the interaction signal network between the cancer and stromal cells are the bases for current cancer therapies. Identification of the mutated components in the intrinsic and extrinsic apoptotic pathways in cancer cells and designing small molecule mimetics or agonists to eradicate cancer cells by selectively targeting these mutations represent the attractive strategies for modern cancer therapy.
Export Options
About this article
Cite this article as:
Wang Shulin, Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells, Current Cancer Therapy Reviews 2014; 10 (1) . https://dx.doi.org/10.2174/157339471001140815152332
DOI https://dx.doi.org/10.2174/157339471001140815152332 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bortezomib Enhances the Antitumor Effects of Interferon-β Gene Transfer on Melanoma Cells
Anti-Cancer Agents in Medicinal Chemistry Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Telomeres and Thyroid Cancer
Current Genomics Metabolic Targeting of Cancers: From Molecular Mechanisms to Therapeutic Strategies
Current Medicinal Chemistry Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Connection between JAK/STAT and PPARγ Signaling During the Progression of Multiple Sclerosis: Insights into the Modulation of T-Cells and Immune Responses in the Brain
Current Molecular Pharmacology Gene Therapy and Targeted Toxins for Glioma
Current Gene Therapy Targeting Tumor Ubiquitin-Proteasome Pathway with Polyphenols for Chemosensitization
Anti-Cancer Agents in Medicinal Chemistry Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine NAMPT in Regulated NAD Biosynthesis and its Pivotal Role in Human Metabolism
Current Medicinal Chemistry Novel Approaches for Modulating dUTPase and Uracil-DNA Glycosylase: Potential Uses for Cancer and Viral Chemotherapy
Drug Design Reviews - Online (Discontinued) ErbB Antagonists Patenting: “Playing Chess with Cancer”
Recent Patents on Biotechnology Clinical Analysis Methods of Voice Disorders
Current Bioinformatics Effect of Liposomes with Different Double Arms Polyethyleneglycol on Hepatic Metastasis Model Mice and Evaluation Using a Fluorescent Imaging Device
Current Drug Delivery Modulation of Matrix Metalloproteinases by Plant-derived Products
Current Cancer Drug Targets Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Analysis of miRNAs Targeting 3’UTR of H2AFX Gene: a General <i>in Silico</i> Approach
MicroRNA Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry The Role of E-Cadherin Down-Regulation in Oral Cancer: CDH1 Gene Expression and Epigenetic Blockage
Current Cancer Drug Targets Recent Innovations in Antibody-Mediated, Targeted Particulate Nanotechnology and Implications for Advanced Visualisation and Drug Delivery
Current Nanoscience